Ergoteles’s Edgewise Therapeutics EWTX Stock Holding History

Ergoteles’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-34,600	Closed	-$275K	–	1670
2022 Q2	$275K	Buy	+34,600	New	+$262K	0.01%	1148

Other funds holding EWTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ergoteles's EWTX Position: Q3 2022 in Review

Ergoteles sold out of Edgewise Therapeutics (EWTX) in Q3 2022, closing a stake of 34,600 shares — an estimated $275K sold.

Ergoteles first reported a position in EWTX in Q2 2022 and held it in 1 quarter. The position peaked at $275K in Q2 2022. 94 funds tracked by Wall St. Rank hold EWTX as of Q3 2022.

Ergoteles reported no remaining Edgewise Therapeutics position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 34,600 Edgewise Therapeutics shares in Q3 2022, an estimated $275K.
Ergoteles first reported a position in Edgewise Therapeutics in Q2 2022 and held it in 1 quarter.
Ergoteles's Edgewise Therapeutics position peaked at $275K in Q2 2022.
94 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.